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Abstract
Background: Curcumin is known to possess many anti-tumor properties such as inhibition of tumor growth and
induction of apotosis. However, limited bioavailability of curcumin prevents its clinical application. A synthesized
curcumin analog, 1,5-diaryl-3-oxo-1,4-pentadiene such as GO-Y030, has the improved anti-tumor potential in vitro
as well as in mouse model of colorectal carcinogenesis.
Results: These compounds were divided into two groups; one is the higher anti-proliferative group, in which
79.7% of 1,5-diaryl-3-oxo-1,4-pentadienes were clustered. One of the 1,5-diaryl-3-oxo-1,4-pentadiene analogs, GO-
Y078 has the most enhanced growth inhibition, and its solubility was improved, compared with curcumin. GO-
Y078 inhibits NF-B transactivation, as well as expression of TP53 and DR5 more effectively than curcumin. In a
mouse model, GO-Y078 presented 1.4 fold more survival elongation that was not achieved by curcumin and GO-
Y030.
Conclusions: The 1,5-diaryl-3-oxo-1,4-pentadiene analogs can yield good lead compounds for cancer
chemotherapy, to overcome low bioavailability of curcumin.
Background
Naturally derived products are the most valuable source
for drugs and their lead compounds. Approximately
74% of anticancer drugs are either natural products or
their derivatives [1]. Curcumin, 1,7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione, is a dietary
constituent of turmeric. It is well known for its ability
to suppress tumor growth [2]. The mechanisms of its
tumor suppression have been examined at the molecular
level. Curcumin is known to interfere with the transacti-
vation of nuclear factor-B( N F - B) [3], activator pro-
tein 1 [4], and b-catenin [5] thus resulting in the
negative regulation of various oncogenes such as c-Myc,
cyclin D1, Bcl-2,a n dBcl-XL. Curcumin arrests the cell
cycle at G0/G1 and/or G2/M through the upregulation
of the cyclin-dependent kinase inhibitors p21 and p27,
and the downregulation of Cdc2 and cyclin B1 [6]. Cur-
cumin blocks signaling of growth factors, including
human epidermal growth factor receptor-2 [7], platelet-
derived growth factor [8] and fibroblast growth factor
[9]. It also blocks Wnt signalling [10]. Curcumin also
has anti-invasive, antimetastastic, and antiangiogenic
properties [11,12]. Therefore, curcumin is labeled as a
multi-targeted drug. However, the systemic availability
of curcumin remains negligible [13,14]. Hydrophobicity,
low absorption, and rapid metabolism have been consid-
ered as reasons for curcumin’s low bioavailability [2]. To
address this issue, we synthesized a series of curcumin
analogs and screened them. An analog named GO-Y030
was synthesized that possessed 30- to 50-fold enhanced
antiproliferative potential against various types of can-
cers in vitro [15]. The molecular mechanisms of GO-
Y030 closely resembled those of curcumin. Oral admin-
istration of GO-Y030 prevented the adenoma formation
in the familial adenomatous polyposis (FAP) mouse
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demonstrated that the number and the size of b-cate-
nin-positive adenomas were reduced. In this case, bioa-
vailability of GO YO30 was not an issue because it can
be directly delivered to the gastrointestinal tract. How-
ever, GO-Y030 was hydrophobic and ineffective to the
treatment of peritoneal carcinomatosis (PC) of gastric
carcinoma in a mouse model. These observations led us
to additionally synthesize hyperactive curcumin analogs
in order to optimize their pharmacological potential.
Results
Screening of the hyperactive growth inhibitors among
the newly synthesized curcumin analogs
Eighty eight curcumin analogs, including 69 species of
DOPs, curcumin and 1,7-diaryl-1,6-heptadiene-3,5-
dione, and 17 species of non-DOP analogs were synthe-
sized (Figure 1). The growth-suppressive potential of
these compounds was then examined on cell panels
composed of 16 types of cancers. These included gastric
cancers (GCIY and SH10TC), colon cancers (HCT116,
DLD1 and SW680), lung cancer (A549), pancreatic can-
cer (PK1), kidney cancer (ACHN), liver cancer (HUH7),
ovarian cancer (OVK18), breast cancer (MCF7), skin
cancer (A431), bile duct cancer (HuCCT1), thyroid can-
cer (8505c), melanoma (G361), and prostate cancer
(PC3). The IC50 value of each analog was calculated
against the individual cell line. These values were
analyzed using cluster analysis (Figure 2). Resulting
from the pattern of inhibition, 88 curcuminoids were
divided into 2 clusters; one is the high IC50 group
(Group a) composed of 29 analogs, and the other is the
low IC50 group (Group b) composed of 59 analogs. In
detail of Group a, 51.7% (15/29) of those are DOPs,
Figure 1 Chemical structures of curcuminoids.T w ot y p e so f
basic structure of 1,5-diaryl-3-oxo-1,4-pentadienes are presented.
Figure 2 Cluster analysis of growth inhibition of 88
curcuminoids. The IC50 values are graded by coloring from red (0
μM) to cyan (50 μM). Eighty eight analogs are lined in
perpendicular, and 16 cancer cell lines are lined in horizontal. Group
a is composed of the analogs with the high IC50 values, and Group
b composed of analogs with the low IC50 values, and Group c
includes the analogs with the lowest IC50 values. The analogs
enclosed with red rectangle are DOPs, and the analogs attached
with closed circle are non-DOPs. Acyclic DOPs are indicated by
open circle. Blue arrows indicate the analogs of which predictive
values of solubility are better than curcumin.
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v i e wp o i n to fD O P s ,5 5o u to f6 9( 7 9 . 7 % )b e l o n gt o
Group b. In this study, 64 species out of 69 analogs are
classified to acyclic DOPs, and 81.3% species (52/64) of
acyclic DOPs belong to Group b. On the other hand,
among 17 non-DOPs, 82.4% species belong to Group a.
The analogs that exhibited the strongest potential
against all of the cell lines were clustered in Group c
(Figure 2). This cluster included GO-Y078, 079, 030,
097, and 098. All of these compounds had at least 10
times higher growth-suppressive potential than curcu-
min. For example, the value of GO-Y030 reached 76
times, GO-Y078 84 times, and GO-Y079 29 times
higher than curcumin against GCIY. In the solution, as
each ethoxyethyl group of GO-Y079 and 097 is pre-
dicted to be hydrolyzed in an acidic environment, and
GO-Y079 and GO-Y097 can convert themselves to 078
and 098, respectively. Essentially, GO-Y078 is nearly
identical to 079, and 098 to 097, just as shown in the
cluster analysis. For this reason, we excluded GO-Y079
and 097 from further examination. In this analysis, it
has been shown A549 and MCF7 were rather resistant
to curcumin analogs among them (Figure 2).
Improvement in solubility of curcumin analogs
The ADME profiles of 100 curcuminoids, including virtual
analogous compounds were determined in silico. Concern-
ing solubility of analogs, the predicted values of top 15 are
represented in the bar graph (Figure 3a). Analogs, that
bear the improved solubility than curcumin and belong to
Group b at the same time, are 8 compounds including
GO-Y078 and Y098. The predictive values of them are
1.98 and 2.93 times higher than curcumin, respectively.
The highest predictive valuei s1 1 . 7m g / Lo fG O - Y 0 3 8 ,
Figure 3 Solubility of curcumin analogs.( a )in silico prediction of solubility. The blue bar indicates analog belonging to Group a in Figure 2,
and the red indicates Group b. The analogs labeled gray were not analyzed in Figure 2. (b) Chemical structure of DOPs bearing the lowest IC50
value and higher solubility. The methoxy group is indicated as MeO, and the methoxymethoxy group indicated as MOMO. (c) Appearance of the
diluted solution of curcuminoids. Curcumin and its analogs were dissolved in ethanol-cremophor EL
® at nearly the maximum concentration
denoted in each column, then diluted serially with PBS. The dilution ratio is depicted at the top of each column. Aggregation is labeled as Agg.
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Y030, the solubility is 0.48 times lower than curcumin.
Then, we practically examined the solubility of curcumin,
GO-Y030, 078, and 098 (Figure 3b). These compounds
were first dissolved in ethanol-cremophor EL
® and then
diluted in PBS. Concentration of GO-Y078 in ethanol-cre-
mophor EL
® reached the highest level among them at 300
mM. While there were no aggregations seen in GO-Y078
and 098 solutions after 4 serial dilutions, the appearance
of aggregation was observed in curcumin and GO-Y030
solutions immediately after the first dilution (Figure 3c).
In fact, GO-Y078 and 098 showed increased solubility, as
predicted.
Growth suppression and apoptosis induction potencies of
GO-Y030, 078, and 098
To examine the growth suppression of 3 DOP analogs,
GO-Y030, Y078, and Y098 clustered in Group c, the
analysis of cell cycle progression in HCT116 cells was
conducted by flow cytometry. Analysis of cell cycle pro-
gression indicated the increase of the subG1 fraction.
Those treated with GO-Y030, 078, and 098 at 2 μM
were 27.2%, 17.1%, and 19.8%, respectively. These values
were 6.0, 3.8, and 4.4 times higher than curcumin at the
same concentration (Figure 4a). GO-Y030, 078, and 098
may have a stronger potency to induce apoptosis than
curcumin. To further elucidate this observation, caspase
cleavage reactions were assessed. At a dose of 2 μM, the
amount of cleaved product in GO-Y030, 078, and 098
treatments were 2.12 ± 0.07, 3.47 ± 0.84 and 1.67 ± 0.19
times higher, respectively, than curcumin. GO-Y030,
078, and 098 were also considered to be potent inducers
of apoptosis (Figure 4b).
GO-Y030, 078, and 098 can induce apoptosis through
numerous mechanisms just as curcumin
Generally, cancer cells have some breakdown in key
apoptosis induction mechanisms. These include the
Figure 4 Apoptosis induction by GO-Y030, 078, and 098. (a) FACS analysis. Percentage of cells cycling in each phase, G0/G1,S ,a n dG 2/M
including subG1 is represented in the column. (b) Effect on caspase induction. Caspase cleavage reaction was assessed by the relative expression
of cleaved cytokeratin 18 against the control (= 1.0). (c) Effects on NF-B transactivation. The relative amount of NF-B p50 subunit binding its
target DNA element, treated with 2 μM analogs in SW620 is indicated, compared to treated controls (TNFa alone, = 1.0). (d) Effects of 2 μM
analogs on TP53 expression. The relative amount of TP53 is represented against the control (= 1.0). (e) Effects on DR5 expression. Relative
expression value against the control (= 1.0) is represented at the bottom. b-actin is labeled as ACTB, and curcumin labeled as Cur.
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as inactivation of the TP53 pathway, and extrinsic apop-
totic pathways. Hyperactivated NF-B in cancer cells
leads to protection from apoptotic cell death via its tar-
gets including IAPs. It is well documented that curcu-
min can inhibit NF-B transactivation [3,4]. The
inhibitory effects of NF-B transactivation in 3 DOP
analogs, were examined by ELISA. In this assay, NF-B
transactivation was estimated by the amount of p50 sub-
unit binding to its DNA consensus sequence. NF-B
p50 activates a set of target genes in response to certain
inflammatory signals, such as TNFa.I nt h i ss t u d y ,c u r -
cumin and DOP analogs decreased TNFa-induced NF-
B transactivation at a dose of 2 μM. The relative values
of transactivation with curcumin, GO-Y030, 078, and
098 were 0.32 ± 0.02, 0.16 ± 0.05, 0.26 ± 0.07, and 0.40
± 0.01 compared to the control (= 1.0) (Figure 4c).
These DOPs were shown to have comparative potency
to curcumin in the inhibition of NF-B transactivation.
The p53 gene is altered in nearly half of human can-
cers, usually by point mutations, and results in the loss
of ability to induce pro-apoptotic genes. Following 24 h
of treatment, TP53 induction was assessed in HCT116
cells bearing wild-type p53 as a control. After treatment
with a 2 μM dose, the TP53 expression in curcumin-
treated cells was similar to the control level, while the
levels of TP53 in GO-Y030, 078, and 098 were increased
2.32, 1.54, and 1.52 times higher, respectively, than the
control. (Figure 4d). Activating certain death receptors
(DR), particularly DR4 and DR5, has been shown to
selectively kill cancer cells while sparing normal cells
[21]. Curcumin activates DR5, but does not activate
DR4 [22]. DR5 is regulated by either a p53-dependent
or -independent mechanism [23]. DR5 overexpression
induces ligand-independent apoptosis [24]. The expres-
sion of DR5 was estimated in DLD-1 bearing mutant
TP53, by Western blotting. After 24 h of incubation, the
expression of DR5 was increased to 3.58, 6.20, and 2.39
times higher than the control, in GO-030, 078, and 098
treated cells, respectively (Figure 4e). It was shown that
the apoptosis induction potency, including overexpres-
sion of TP53 and DR5 was improved, but NF-B inhibi-
tion was not.
Therapeutic effects of DOP analogs in an experimental
mouse model
According to the data concerning solubility described
above, GO-Y078 and 098 may have improved bioavail-
ability. Initially, the toxicity of these compounds was
examined in vitro. We examined the growth suppression
of the primary normal liver cells, hNHeps
® with GO-
Y030, 078, and 098. They do not affect survival nor
have any toxic effects to hNHeps
® a td o s e sa sh i g ha s
50 μM. Then, we conducted a single IP injection, and
determining the maximum tolerable dose (MTD). The
MTDs of GO-Y030 and 078 were determined to be
474.5 and 400 mg/kg, respectively. Administration of
these doses did not affect the animals for over 1 month.
However, the MTD of GO-Y098 was rather toxic at a
dose below 204 mg/kg, and this compound was
excluded from further examination. The compounds
were then applied to the mouse model of PC with
GCIY, a gastric cancer notorious for its rapid progres-
sion [25]. The PC progresses very rapidly, and increases
in ascites fluid and comparative weight gain continues
until the animal dies. As a result, mortality occurs
within 1 month following tumor inoculation. Experi-
mental treatment was carried out as shown in Figure 5a.
The IP administration of curcumin had no effect on the
PC model, where the average body weight of untreated
group reached to 164.0 ± 20.8% of that before treat-
ment, whereas that treated with curcumin to 150.2 ±
24.0% (P = 0.18). GO-Y030 had a significant antitumor
effect on PC progression (p<0 . 0 0 1 ,F i g u r e5 b ) ,b u tn o
survival benefit was observed (Figure 5c). Similar to that
of GO-Y030, GO-Y078 showed a significant suppression
of PC progression. At the 17th day after the first treat-
ment, the average body weight of the untreated group
was 35.9 ± 2.6 g due to increased ascites fluid accumula-
tion, while that of the treated group was significantly
less at 29.1 ± 2.5 g (p = 0.003, Figure 5d). The average
body weight before inoculation was 28.4 ± 0.9 g, there-
fore the ascites fluid accumulation was considered to be
completely suppressed by GO-Y078 treatment. Survival
time of the untreated group (n = 4) ranged from 21 to
23 days, with a median survival time (MST) of 22 days.
Survival time of the GO-Y078 treated group (n = 6) ran-
ged from 25 to 109 days, with a MST of 30.5 days.
Treatment with GO-Y078 led to an approximate 40%
increase in survival time. Log-rank analysis significantly
indicated a survival benefit of GO-Y078 treatment (p =
0.01, Figure 5e). Judging from these results, the bioavail-
ability of GO-Y078 is significantly higher than GO-
Y030. In order to examine why the survival was limited
in the GO-Y078 treated mice, despite the fact that the
ascites fluid accumulation disappeared completely.
When necropsies were performed, in nearly all of the
GO-Y078-treated mice, residual cancer cells were
observed to colonize around the stomach, pancreas, bile
duct, and duodenum. Direct invasion to the pancreas,
liver, and duodenum was thought to be the causes of
death.
Discussion
DOP analogs possess common structural feature, that is
an electrophilic a,b-unsaturated ketone, which reacts
with nucleophilic groups through the Michael addition.
Then, the ketone binds covalently with thiol groups of
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group does not exist in DNA, curcuminoids do not
attach DNA itself, different from the cytotoxic che-
motherapeutic agents. Two independent proteins can be
alkylated through two a,b-unsaturated double bonds in
DOP that stretch from the center ketone moiety toward
both ends [27]. In this alkylation, an association of a
cysteine protease, such as caspase, and its target protein
may assist in the catalytic reaction of caspase, resulting
in target degradation. In our previous study, we
observed that DOP analogs increased caspase activity,
and a caspase inhibitor inhibited the degradation of b-
catenin or KRAS by DOP analogs [15]. Although this
contention remains unproven, perhaps this center struc-
ture of DOP confering Michael addition is responsible
for the multi-targeted nature of curcuminoids. Contribu-
tion to enhanced potency by the alteration from a
diketone to a monoketone also remains to be elucidated.
Shortening the chemical distance by alkylation through
conversion from a di- to monoketone structure may
result in an enhanced potential. Acyclic DOP analogs
have an enhanced cytotoxicity [27]. Substitution in each
aromatic ring could improve solubility and the resultant
pharmaceutical potency. As the symmetry of the attach-
ment group of each aromatic ring is not necessary,
further improvement of solubility may be achievable by
various types of substitution in this portion [17]. The
hydrophilic nature and total positioning of the attached
groups in a compound can reflect the potency of the
analogs. In this study, the maximum IC50 value of DOP
analogs reached a level that was 84 times lower than
curcumin. The data, that curcuminoids could only affect
the malignant growth, lead to the hypothesis that the
growth-suppressive potential of these analogs depends
Figure 5 Experimental treatment with GO-Y078 and 030 in mice. (a) The schedule of experimental treatment. (b) Antitumor effect of GO-
Y030. The body weight corresponding to the progression of PC, were evaluated. V, ethanol-cremophor, 30; Y030 155 mg/kg. (c) Survival benefit
of GO-Y030. (d) Antitumor effect of GO-Y078. The body weight corresponding to the progression of PC was evaluated at the 17th day. V,
ethanol-cremophor; †, 133 mg/kg; ‡, 266 mg/kg (e) Survival benefit of GO-Y078.
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pressed in malignant cells. That might be a reason why
curcuminoids are rather safe to normal cells.
Furthermore, it has been shown that some of DOP
analogs induce more cell death to cancer cells, com-
pared with curcumin. Apoptosis related proteins, such
as TP53 and DR5 were up-regulated with DOP analogs
more efficiently than curcumin. However, the precise
mechanisms of up-regulation are still unknown [28].
Cancer cells invent numerous ways to inactivate many
of the apoptotic pathways. The pluripotent apoptosis
induction by curcuminoids could overcome complexity
of antiapoptosis in cancer cells. One of DOP analog,
GO-Y078 has shown survival benefit in mouse PC
model for the first time. That could not be achieved by
GO-Y030. Although these two DOPs presented the
same level of IC50 values, the predicted solubility of
GO-Y078 was 1.98 mg/L, whereas that of GO-Y030 was
0.26 mg/L. In fact, GO-Y030 was less soluble compared
with GO-Y078. The difference of solubility between
GO-Y030 and GO-Y078 probably influences the differ-
ence in their survival benefits in the PC models. More-
over, additional times of administration of GO-Y078
may lead to further improved survival. Combined treat-
ment with conventional cytotoxic agents, such as 5-FU
and taxanes, or a DR5 ligand, for example, tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL),
may synergistically induce better outcomes [22].
Recently, off-target toxicity has become a problem in
molecular-targeted medicines which have already been
approved [29,30]. Some of the potent DOP analogs may
not be as safe as dietary curcumin, shown with GO-
Y098, and we should be cautious against that during
development.
Conclusions
Synthesis of DOP analogs represented by GO-Y078 can
overcome low bioavailability of curcumin, yielding good
lead compounds for new cancer chemotherapeutic
agents bearing multi-target properties.
Methods
Chemicals
Chemical synthesis, physical properties and molecular
formulas of the newly synthesized curcumin analogs
have been previously described [15,17]. See additional
file 1: Physical properties of new curcumin analogs. Cur-
cumin (Sigma-Aldrich) and its analogs were dissolved in
DMSO at 10-50 mmol/L as a stock solution. Cremophor
EL
® was purchased from Sigma-Aldrich.
Cell lines
GCIY, HCT116, DLD1, SW680, A549, PK1, ACHN,
HUH7, OVK18, MCF7, 8505c, G361, and PC3 were
obtained from the Cell Resource Center for Biomedical
Research (Institute of Development, Aging and Cancer,
Tohoku University, Sendai, Japan). ACHN was obtained
from the American Type Culture Collection (ATCC).
HuCCT1, SH10TC, and A431 were obtained from Riken
Cell Bank Normal human primary hepatocytes
(hNHeps
®) were purchased from Lonza. Cells were cul-
tured in RPMI 1640 medium containing 10% fetal
bovine serum.
Growth-suppression analysis
Growth-suppressive effects of the derivative compounds
were measured in different cancer cell lines for 72 h.
Cell viability was assayed by quantifying the uptake and
digestion of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophe-
nyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium
salt according to the manufacturer’s instructions
(Dojindo Laboratories) by 96-well plate reader, Spectra-
Max M2e (Molecular Devices). The percentage cell
growth of the control, which was treated with 1%
DMSO alone, was calculated and plotted, and the mean
growth-inhibitory concentration (IC50) value was then
determined.
Cluster analysis
Clustering analysis among analogs was performed with
MultiExperiment Viewer software (MeV) from the insti-
tute for Genomic Research at that time [18].
Cell Cycle analysis
Cell cycle phase was determined by fluorescence-acti-
vated cell sorting analysis. Cells from the HCT116 cell
line were inoculated into 6-well plates at a concentra-
tion of 5 × 10
5 per well, exposed to the derivative com-
pounds at various concentrations, cultured for 24 h, and
collected and sorted using a Cytomics FC500 Flow
Cytometry System (Beckman Coulter, Inc.) as previously
described [19]. The percentage of each cell fraction cor-
responding to the subG1,G 0/G1,S ,a n dG 2/M phases
was calculated using WinCycle Software (Beckman).
Expression analysis
HCT116 cells treated by the analogs were cultured for
24 h, collected and lysed with lysis buffer (500 mM
Tris-HCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 1 mM
sodium orthovanadate, and 1% NP-40). After centrifu-
ging samples, the supernatant fraction was transferred
to a fresh tube. Samples were mixed with 5× SDS sam-
ple buffer (312.5 mM Tris-HCl pH 6.8, 50% Glycerol,
25% 2-mercaptoethanol, 12.5% SDS, and 0.1% bromo-
phenol blue) before western blotting. Antibodies used
for Western blotting were anti-beta-actin monoclonal
antibody (A2066, Sigma-Aldrich), anti-DR5 monoclonal
antibody (Santa Cruz Biotechnology), and Alexa Fluor
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quantification was conducted using the Odyssey detec-
tion system (LI-COR). Expression of TP53 was mea-
sured using P53 ELISA kit (Promokine) according to the
manufacturer’s instructions. Samples were collected
using the same method as Western blotting. Twenty
micrograms of protein were incubated in wells coated
with anti-human p53 antibody. Biotin-conjugated anti-
human p53 antibody was then added. After incubation,
streptavidin conjugated with horse radish peroxidase
(HRP) was added. Tetramethyl-benzine, which reacts
with HRP, was then added and the absorbance was mea-
sured at 450 nm by SpectraMax M2e.
Caspase cleavage reaction
HCT116 cells were inoculated at a concentration of 1 ×
10
4 per well in a 96-well plate, cultured until cells were
semi-confluent, and treated with the analogs for 24 h.
Serum from each sample was collected, duplicated, and
assessed by ELISA using HRP-conjugated M30 mono-
clonal antibody (M30-Apoptsense
® ELISA, Peviva)
according to the manufacturer’s instructions. Anti-M30
monoclonal antibody recognizes a soluble cytokeratin18-
Asp396 molecule that becomes exposed after cleavage
by caspases (caspase3, 6, 7, and 9) during apoptosis. The
absorbance was measured by SpectraMax M2e at 450
nm. These analyses were conducted in triplicate.
NF-B transactivation
NF-B transactivation was measured by ELISA using a
NFB p50 Transcription Factor Assay kit (Thermo
Scientific) according to the manufacturer’s instructions.
SW620 cells were treated with the compounds with or
without Tumor Necrosis Factora (TNFa)( 1 0n g / m l ,
Sigma) for 6 hours, washed with phosphate buffered sal-
ine (PBS), and lysed with provided M-PER
® lysis buffer
(Thermo Scientific). Whole-cell extracts containing 20
μg of protein were added with biotinylated-NF-Bc o n -
sensus DNA sequence to a streptavidin-coated 96-well
plate. Sample wells were incubated with the monoclonal
antibody against NF-B p50, and then incubated with
HRP-conjugated secondary antibody. Luminol/enhancer
solution and stable peroxide solution were added and
NF-B transactivation was detected using an LMax
Luminometer (Molecular Devices).
In silico ADME analysis
Absorption, distribution, metabolism, excretion (ADME),
and solubility, were analyzed in silico by ADMEWORKS/
Predictor (Fujitsu Kyushu Systems Ltd.). This analysis is
commercially available and depends on a quantitative
structure-activity relationship [20]. Solubility was calcu-
lated by the linear multiple regression equation and indi-
cated by the predicted value.
Animal experiment
C57BL/6J mice were obtained from CLEA Japan, Inc.
and KSN Slc (nu/nu) mice were obtained from Japan
SLC. The injection solution was prepared by first dissol-
ving the analogs with ethanol-cremophor EL
® (1:1) and
then diluting the solution 1:8 with PBS. C57BL/6J mice
were used for the assessment of toxicity of the C5-cur-
cuminoids. The maximum tolerable dose (MTD) was
determined by a single intraperitoneal (IP) administra-
tion. Therapeutic experiments were conducted with the
IP administration of 155 mg/kg of GO-Y030 (total
volume 1.0 mL). IP administration of GO-Y078 was
conducted with 133 mg/kg or 266 mg/kg doses. Etha-
nol-cremophor EL
® alone diluted 1:8 with PBS was
injected as a control. The PC model was established by
inoculating 5 × 10
6 GCIY cells into the abdominal cav-
ities 6-week-old male KSN/Slc mice, 1 week prior to
treatment with the 1,5-diaryl-3-oxo-1,4-pentadiene
(DOP) analogs. Pathological examination including
hematoxylin-eosin staining was performed as previously
described [16]. All animal experiments were performed
in accordance with approved institutional animal use
guidelines (Tohoku University) based on international
guideline.
Statistic analysis
Each experiment was conducted three times, unless spe-
cified otherwise. Individual values were compared by
Student’s t-test. The survival curve was drawn using the
Kaplan-Meier method and compared using the log rank
test.
Additional material
Additional file 1: Physical properties of new curcumin analogs. The
physical properties and molecular formula of the analogs are described
in the file.
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